These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35835061)

  • 21. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
    Savas PS; Hemsley KM; Hopwood JJ
    Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
    Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
    Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome.
    Muschol N; Pohl S; Meyer A; Gal A; Ullrich K; Braulke T
    Am J Med Genet A; 2011 Jul; 155A(7):1634-9. PubMed ID: 21671382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoxetine ameliorates mucopolysaccharidosis type IIIA.
    Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL
    Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
    King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose genistein in Sanfilippo syndrome: A randomised controlled trial.
    Ghosh A; Rust S; Langford-Smith K; Weisberg D; Canal M; Breen C; Hepburn M; Tylee K; Vaz FM; Vail A; Wijburg F; O'Leary C; Parker H; Wraith JE; Bigger BW; Jones SA
    J Inherit Metab Dis; 2021 Sep; 44(5):1248-1262. PubMed ID: 34047372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of mucopolysaccharidosis III-A (Sanfilippo Syndrome-A) in dried blood spots (DBS) by tandem mass spectrometry.
    Yi F; Hong X; Kumar AB; Zong C; Boons GJ; Scott CR; Turecek F; Robinson BH; Gelb MH
    Mol Genet Metab; 2018 Sep; 125(1-2):59-63. PubMed ID: 30006231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
    King B; Savas P; Fuller M; Hopwood J; Hemsley K
    Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
    Perkins KJ; Muller V; Weber B; Hopwood JJ
    Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.
    Haurigot V; Marcó S; Ribera A; Garcia M; Ruzo A; Villacampa P; Ayuso E; Añor S; Andaluz A; Pineda M; García-Fructuoso G; Molas M; Maggioni L; Muñoz S; Motas S; Ruberte J; Mingozzi F; Pumarola M; Bosch F
    J Clin Invest; 2013 Aug; 123(8):3254-3271. PubMed ID: 23863627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-onset mucopolysaccharidosis type IIIA mimicking Usher syndrome.
    De Falco A; Karali M; Criscuolo C; Testa F; Barillari MR; Scarpato M; Gaudieri V; Cuocolo A; Russo A; Nigro V; Simonelli F; Banfi S; Brunetti-Pierri N
    Am J Med Genet A; 2024 May; 194(5):e63517. PubMed ID: 38149346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Alexanderian D
    Mol Genet Metab; 2021; 134(1-2):175-181. PubMed ID: 34247932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group.
    Köhn AF; Grigull L; du Moulin M; Kabisch S; Ammer L; Rudolph C; Muschol NM
    Mol Genet Metab Rep; 2020 Jun; 23():100578. PubMed ID: 32226768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients.
    Naimy H; Powell KD; Moriarity JR; Wu J; McCauley TG; Haslett PA; Barbier AJ; Qiu Y
    Bioanalysis; 2016 Feb; 8(4):285-95. PubMed ID: 26847798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.